Leerink Partners Initiates Coverage On Tenaya Therapeutics with Outperform Rating, Announces Price Target of $7
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners analyst Mani Foroohar has initiated coverage on Tenaya Therapeutics (NASDAQ:TNYA) with an Outperform rating and set a price target of $7.
November 30, 2023 | 1:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Leerink Partners initiated coverage on Tenaya Therapeutics with an Outperform rating and a price target of $7.
The initiation of coverage by Leerink Partners with an Outperform rating typically indicates a positive outlook on the stock by the analyst. The announcement of a price target higher than the current market price suggests an expectation of the stock's future appreciation, which can positively influence investor sentiment and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100